Is NOVT a Buy? What to Consider in 2026

Short answer

The bull case for NOVT (NOVT) rests on Medical Solutions demand: The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Revenue (TTM) is ~$1.0 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. Whether NOVT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest. Novanta grows through a mix of organic gains in its OEM franchises and a steady cadence of bolt-on acquisitions that add technology and expand its addressable market. The investment picture is that of a diversified precision-components compounder: modest single-digit organic growth in a typical year, higher reported growth when acquisitions are added, and expanding adjusted margins, all of which the market has historically rewarded with a premium valuation. The trade-off is that the stock's high price-to-earnings multiple makes it sensitive to any slowdown in medical or industrial capital spending, integration missteps, or margin pressure, so the shares can be volatile around earnings and macro shifts.

What's the case for buying NOVT?

1. Medical Solutions demand.

The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Novanta supplies embedded photonics, motion, and radio-frequency technologies to medical-device OEMs, giving it exposure to durable healthcare spending trends. Demand here tends to be less cyclical than industrial markets, which supports steadier revenue.

2. Automation and robotics.

The Automation Enabling Technologies segment sells precision motion, machine vision, and laser components into robotics, industrial automation, and laser materials processing. Novanta reported strong bookings growth with a book-to-bill ratio above 1.0 in early fiscal 2026, pointing to recovering order momentum. This unit ties Novanta to long-run automation and reshoring themes, though it is more sensitive to the industrial capital-spending cycle.

3. Acquisitions and margin expansion.

Novanta has a long track record of bolt-on acquisitions that add proprietary technology, broaden its OEM relationships, and expand its addressable market. Management pairs this with a focus on adjusted EBITDA margin expansion and pricing discipline. Successful integration is central to the growth story, since much of the company's reported revenue growth in a given year can come from deals rather than pure organic gains.

4. Improving order momentum.

In its Q1 fiscal 2026 report, Novanta cited bookings up about 37% year over year with double-digit bookings and revenue growth across all business units, and it raised its full-year revenue and earnings outlook. Rising bookings and a book-to-bill above 1.0 suggest the backlog is building. Whether that momentum converts into sustained organic growth depends on end-market demand holding up.

What are the risks to NOVT?

Novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.

How is NOVT valued? (as of July 2026)

Price

$146.32

Market cap

$5.21B

P/E (TTM)

105.26

Forward P/E

35.31

Price / book

3.97

Beta

1.67

52-week range

$98.27 to $171.85

Snapshot for NOVT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$1.0 billion
Q1 FY2026 revenue: ~$258 million (up ~10% YoY)
FY2026 revenue guidance: ~$1,040-1,055 million
Adjusted EPS guidance (FY2026): ~$3.50-3.65
Adjusted EBITDA guidance (FY2026): ~$245-250 million
Market cap: ~$5.7 billion
P/E (trailing): ~100x
P/E (forward): ~41x

Novanta trades at a rich valuation, with a trailing price-to-earnings ratio near 100x and a forward multiple around 41x, reflecting the market's view of it as a durable, high-margin precision-technology compounder. GAAP earnings are held down by acquisition-related amortization and stock compensation, so the company and analysts emphasize adjusted EPS and adjusted EBITDA. That premium multiple means the shares can react strongly to any change in the growth or margin trajectory.

How do you decide if NOVT is a buy?

Rather than asking whether NOVT is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold NOVT indirectly through an index or sector ETF before adding more.

For the full picture, see the NOVT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NOVT against your real portfolio and see your actual exposure before deciding.

The bottom line on NOVT

The bottom line: NOVT's story right now is Medical Solutions demand, with revenue (ttm) at ~$1.0 billion. If you believe that narrative continues, the call is about sizing NOVT sensibly and checking overlap with what you own; if you doubt it (the risk: novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around NOVT with Walnut

Use NOVT as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is NOVT a good stock to buy right now?

The case for NOVT right now is Medical Solutions demand, with revenue (ttm) at ~$1.0 billion. If you believe that thesis holds, NOVT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does NOVT do?

Novanta Inc.

What are the main risks of NOVT?

What does Novanta do?

Novanta is a precision technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems. It sells these to original equipment manufacturers in medical and advanced industrial markets, where its parts are embedded inside customers' larger machines and instruments.

What are Novanta's business segments?

Novanta reports two segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and electronics manufacturing. Medical end markets are a bit over half of revenue and advanced industrial the rest.

How much revenue does Novanta generate?

Novanta generates roughly $1.0 billion in trailing-twelve-month revenue as of July 2026. Its Q1 fiscal 2026 revenue was about $258 million, up around 10% year over year, and management guided full-year 2026 revenue to roughly $1,040-1,055 million.

Does Novanta pay a dividend?

Novanta does not pay a regular dividend. The company reinvests its cash flow into research and development and bolt-on acquisitions to fund growth, so returns to shareholders have historically come from share-price appreciation rather than income.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NOVT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.